Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 1:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Clobetasol Propionate Clear all
Not listed Phase 4 Interventional

Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia

NCT01111981
View directory record Official record
Conditions
Alopecia
Interventions
Clobetasol Propionate 0.05% Emollient Foam
Drug
Lead sponsor
Callender Center for Clinical Research
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Mitchellville, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2010 · Synced Sep 12, 2026, 1:20 PM EDT
Completed Phase 4 Interventional

Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis

NCT00437255
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Clobetasol Propionate, 0.05%, Calcipotriene and betamethasone dipropionate ointment
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 80 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Fridley, Minnesota • Austin, Texas • Bryan, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Sep 12, 2026, 1:20 PM EDT
Active, not recruiting Phase 2 Interventional

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

NCT06120140
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Amivantamab IV, Amivantamab SC, Lazertinib, Doxycycline, Minocycline, Clindamycin, Chlorhexidine, Noncomedogenic skin moisturizer, Ruxolitinib, Tacrolimus, Zinc gluconate, Propranolol, Timolol, Clobetasol
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
28
States / cities
Chandler, Arizona • Duarte, California • Fullerton, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 12, 2026, 1:20 PM EDT
Completed Phase 4 Interventional

Fractionated CO2 Laser With and Without Clobetasol for Treatment of Vulvar Lichen Sclerosus

NCT04951206
View directory record Official record
Conditions
Vulvar Lichen Sclerosus
Interventions
Fractionated CO2-laser, Clobetasol Propionate 0.05% Ointment
Device · Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
San Diego, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 12, 2026, 1:20 PM EDT
Completed Phase 3 Interventional Results available

Clobetasol Propionate Versus Fractionated Carbon Dioxide Laser for the Treatment of Lichen Sclerosus

NCT02573883
View directory record Official record
Conditions
Vulvar Lichen Sclerosus
Interventions
Fractionated Carbon Dioxide Laser, Clobetasol Propionate 0.05% ointment
Device · Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Sep 12, 2026, 1:20 PM EDT
Terminated Phase 2 Interventional Results available

An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-Disease

NCT02123966
View directory record Official record
Conditions
Chronic Graft-versus-Host-Disease, Oral Mucosal Disease Due to Graft-versus-host Disease
Interventions
Sirolimus
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
4 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Sep 12, 2026, 1:20 PM EDT
Completed Not applicable Interventional Results available

Treatment of Staphylococcus Aureus Colonization in Hand Eczema

NCT01591785
View directory record Official record
Conditions
Hand Eczema, Foot Eczema
Interventions
Retapamulin 1% ointment, Placebo
Drug
Lead sponsor
Gary Goldenberg
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Sep 12, 2026, 1:20 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate for Chronic Hand Dermatitis

NCT00828464
View directory record Official record
Conditions
Hand Dermatosis
Interventions
clobetasol propionate
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 2, 2012 · Synced Sep 12, 2026, 1:20 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus

NCT00393263
View directory record Official record
Conditions
Lichen Sclerosus
Interventions
pimecrolimus and clobetasol, clobetasol 0.05% cream
Drug
Lead sponsor
Center for Vulvovaginal Disorders
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 11, 2014 · Synced Sep 12, 2026, 1:20 PM EDT
Completed Phase 4 Interventional Results available

Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%

NCT01893567
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Clobex Spray
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Fort Gratiot, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Sep 12, 2026, 1:20 PM EDT
Terminated Not applicable Interventional Results available

Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis

NCT00470392
View directory record Official record
Conditions
Psoriasis
Interventions
Imiquimod, Clobetasol
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Sep 12, 2026, 1:20 PM EDT
Completed Phase 3 Interventional Results available

Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis

NCT00658788
View directory record Official record
Conditions
Psoriasis
Interventions
clobetasol propionate spray 0.05%, calcitriol ointment
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 80 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
12
States / cities
San Diego, California • Newnan, Georgia • Snellville, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Sep 12, 2026, 1:20 PM EDT
Completed Phase 2 Interventional

Intra-oral Treatment of OLP With Rivelin®-CLO Patches

NCT03592342
View directory record Official record
Conditions
Oral Lichen Planus
Interventions
Clobetasol Propionate
Drug
Lead sponsor
Dermtreat
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
14
States / cities
Hialeah, Florida • Miami, Florida • Augusta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Sep 12, 2026, 1:20 PM EDT
Completed Phase 2 Interventional

Hydroxychloroquine vs. Clobetasol Rinse to Treat Oral Lichen Planus

NCT00102557
View directory record Official record
Conditions
Lichen Planus, Oral
Interventions
Hydroxychloroquine
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 12, 2026, 1:20 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Does Steroid Plus CO2 Laser Improve Lichen Sclerosus Symptoms Compared to Steroids Alone?

NCT05243563
View directory record Official record
Conditions
Vulvar Lichen Sclerosus
Interventions
MonaLisa Touch, Topical steroid
Device · Drug
Lead sponsor
University of South Alabama
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Sep 12, 2026, 1:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pivotal Bioequivalence Study of Topically Delivered Clobetasol Propionate Lotion in Healthy Adult Subjects

NCT00864500
View directory record Official record
Conditions
Healthy
Interventions
Clobetasol Propionate 0.05% lotion, single exposure, Clobex TM 0.05% Lotion, single exposure
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2019 · Synced Sep 12, 2026, 1:20 PM EDT
Completed Phase 4 Interventional Results available

Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis

NCT01745133
View directory record Official record
Conditions
Psoriasis
Interventions
vehicle foam, calcipotriene, calcipotriene + clobetasol propionate
Drug
Lead sponsor
Leon Kircik, M.D.
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 16, 2016 · Synced Sep 12, 2026, 1:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Dose-response "Pilot" Study of Topically Delivered Clobetasol Propionate Lotion in Healthy Adult Subjects

NCT00864240
View directory record Official record
Conditions
Healthy
Interventions
Clobex TM (Clobetasol) 0.05% Lotion, single exposure
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2019 · Synced Sep 12, 2026, 1:20 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Study of Combination Treatment With Excimer Laser, Clobex Spray, and Vectical Ointment in the Treatment of Psoriasis

NCT01012713
View directory record Official record
Conditions
Chronic Stable Plaque Psoriasis
Interventions
Clobex Spray, Vectical Ointment, Excimer Laser
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2015 · Synced Sep 12, 2026, 1:20 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study to Evaluate Vectical in Combination With Clobex Spray to Treatment Plaque Psoriasis

NCT01205880
View directory record Official record
Conditions
Psoriasis
Interventions
Calcitriol ointment, Clobetasol spray
Drug
Lead sponsor
Emer, Jason, M.D.
Individual
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2010 · Synced Sep 12, 2026, 1:20 PM EDT
Completed Phase 4 Interventional Results available

Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp

NCT00881868
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
clobetasol propionate spray 0.05%, Vehicle spray
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
4
States / cities
Los Angeles, California • Evansville, Indiana • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Sep 12, 2026, 1:20 PM EDT
Completed Phase 2 Interventional Results available

Clobetasol for Oral Graft-Versus-Host Disease

NCT01557517
View directory record Official record
Conditions
Oral Chronic Graft vs Host Disease
Interventions
Clobetasol Oral Rinse, Placebo oral rinse
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 14, 2025 · Synced Sep 12, 2026, 1:20 PM EDT
Terminated Phase 2 Interventional Results available

Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06

NCT03179605
View directory record Official record
Conditions
Psoriasis
Interventions
DFD06
Drug
Lead sponsor
Primus Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
9
States / cities
Madera, California • Santa Ana, California • Hialeah, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Sep 12, 2026, 1:20 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis

NCT06042647
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
0.01% Halobetasol, 0.045% Tazarotene, 0.05% Clobetasol Propionate
Drug
Lead sponsor
Dermatology Consulting Services, PLLC
Network
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 12, 2026, 1:20 PM EDT